ArticleJournal of pharmacy & bioallied sciences2025
Artificial Intelligence in Cardiovascular Diagnosis: Innovations and Impact on Disease Screenings.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A bibliometric analysis of artificial intelligence applications in heart failure.Journal of thoracic disease · 2026Article
- Healthcare Providers' Perceptions and Multi-Level Determinants of Adoption of an AI-Powered Electrocardiography Interpretation Clinical Decision Support System in Ethiopia: A Formative Qualitative Study.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Artificial intelligence (AI) is making waves in health care, with ECGs and other imaging data leveraged to diagnose or predict cardiovascular diseases (CVDs). Materials and methods: Various AI models as well as algorithms, such as machine learning (ML) and deep learning (DL) algorithms, have shown good results in the detection of diseases like heart failure, atrial fibrillation, coronary artery disease, and valvular heart disease. AI can help alleviate cognitive burdens on clinicians while improving their diagnostic accuracy, examining huge chunks of data and finding patterns that may not be readily apparent, and finding accurate diagnoses and offering cost effective alternatives to traditional methods. AI based ECG interpretation, for example, CNNs, has been used in CVDs, since early identification is essential; algorithms may help detect high-risk individuals, including asymptomatic patients. Results and conclusion: The potential of AI algorithms is also being extended for predicting the onset of diseases in the future and for predicting the long-term prognosis of diseases. Recent landmark studies have shown an opportunity for AI to detect entities such as aortic stenosis, coronary artery disease, and left ventricular active dysfunction. As AI continues to evolve and integrate into clinical practice, there is great potential for it to improve the early detection and management of cardiovascular diseases and, ultimately, patient results and lessen the strain on medical systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.